Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Leonidas Peltekis"'
Autor:
Leonidas Peltekis, Ioannis Efthimiadis, Nikolaos Prokopakis, Zaharias Christogiannis, Maria Voukelatou, Maria Thoma, Ioannis Sinteles, Adamantios Bourdakis, Alexandros D. Tselepis, Maria E. Tsoumani, Haralampos J. Milionis, Ioannis Giatrakos, Giorgos Hatziathanasiou, Spiros Konstantinou, Nikolaos Kipouridis, Kyriafina Terzoudi, Demosthenes B. Panagiotakos, Konstantinos Vemmos, Evangelos Kazakos, Christos Charmpas, Dimitrios Nikolopoulos, Ioannis Vakalis, Ioannis Ntalas, John A. Goudevenos, Antonios Draganigos, Vassilios Giogiakas, Ioannis Xaraktsis, Giorgos Giannakoulas, Christos S. Stroumbis, Giorgos Goumas, Konstantinos Vardakis, Vasileios Vasilakopoulos, Nikolaos Dimoulis, Karmelos Tsilias, Kallirroi I Kalantzi
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 21:516-525
Background: In the present clinical trial, we compared the efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulfate (CHS) salt in patients eligible to receive clopidogrel. Methods: A prospective 2-a
Autor:
Maria Thoma, Maria Voukelatou, Leonidas Peltekis, Georgios Goumas, Spiros Konstantinou, Demosthenes B. Panagiotakos, Christos Charmpas, Haralampos J. Milionis, Konstantinos Vemmos, Adamantios Bourdakis, John A. Goudevenos, Christos S. Stroumbis, Konstantinos Vardakis, Ioannis Sinteles, Zacharias Christogiannis, Antonios Draganigos, Alexandros D. Tselepis, Georgios Giannakoulas, Maria E. Tsoumani, Nikos Dimoulis, Kyriafina Terzoudi, Ioannis Efthimiadis, Ioannis Ntalas, Karmelos Tsilias, Ioannis Xaraktsis, Vasileios Giogiakas, Nikolaos Kipouridis, Georgios Hatziathanasiou, Evangelos Kazakos, Nikos Prokopakis, Dimitrios Nikolopoulos, John N. Vakalis, Ioannis Giatrakos, Kalliroi I. Kalantzi, Vasileios Vasilakopoulos
Publikováno v:
Current vascular pharmacology. 13(6)
Background: The aim of the present interim analysis was to compare the clinical efficacy and safety of the generic clopidogrel besylate (CB) with the innovator clopidogrel hydrogen sulphate (CHS) salt in patient groups eligible to receive clopidogrel